stockportfolio.pro
Pfizer Inc. (PFE)
Healthcare · Drug Manufacturers - General · NYSE
Pfizer Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.82B | $52.55B | $40.83B | $40.91B | $41.65B | $81.29B | $100.33B | $58.50B | $63.63B | $62.58B |
| Gross profit | $40.50B | $41.32B | $31.84B | $32.85B | $33.17B | $50.47B | $65.99B | $33.54B | $45.78B | $46.51B |
| Net income | $7.21B | $21.31B | $11.15B | $16.03B | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
| Net margin | 13.7% | 40.6% | 27.3% | 39.2% | 22.0% | 27.0% | 31.3% | 3.6% | 12.6% | 12.4% |
Source: Pfizer Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into PFE stock?
At today's market cap of $146.48B, Pfizer Inc. is priced for free-cash-flow growth of about 4.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $9.07B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -5.7%/yr over the last five fiscal years and revenue 8.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Pfizer Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PFE in your portfolio →
Pfizer Inc. financial history by metric
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc. — frequently asked questions
What is Pfizer Inc.'s revenue?
Pfizer Inc. (PFE) reported revenue of $62.58B for fiscal year 2025, down 1.6% from the prior year, according to its SEC filings.
Is Pfizer Inc. profitable?
Yes. PFE earned net income of $7.77B in fiscal 2025, a net margin of 12.4%.
What is PFE's P/E ratio?
Pfizer Inc. trades at a price-to-earnings ratio of about 19.6 based on the latest data in our nightly-refreshed cache.
How fast is Pfizer Inc. growing?
PFE's revenue grew at roughly 8.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Pfizer Inc. have?
As of fiscal year 2025, PFE carried roughly $64.80B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Pfizer Inc.'s gross margin?
PFE's gross margin was 74.3% in fiscal 2025 — gross profit of $46.51B on revenue of $62.58B.
What is Pfizer Inc.'s market cap?
Pfizer Inc. (PFE) has a market capitalization of about $146.48B, based on the latest data in our nightly-refreshed cache.
When does Pfizer Inc.'s fiscal year end?
PFE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into PFE stock?
At today's market cap of $146.48B, Pfizer Inc. is priced for free-cash-flow growth of about 4.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $9.07B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -5.7%/yr over the last five fiscal years and revenue 8.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Pfizer Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.